

Didanosine
Retiré
Description générale

INN
Didanosine
Codes ATC

[J05AF02](#)

Type de médicament
Chemical agent

Historique des statuts LME

Ajouté pour la première fois en 2002 ([TRS 914](#)) pour [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Retiré en 2015 ([TRS 994](#)) pour [Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)

Wikipédia

[Didanosine](#)

DrugBank

[Didanosine](#)

Recommandations

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)